Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies
about
Challenges and advances in the assessment of the disposition of antibody-drug conjugatesAntibody Drug Conjugates: Nonclinical Safety Considerations.Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates.Prospects and progress of antibody-drug conjugates in solid tumor therapies.New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds
P2860
Q28085074-B5528622-D740-4F88-870B-CC1F9732AF15Q35967917-DF59ED4B-E19C-4839-B6E4-E9007DD64D6EQ38645927-7B37CCD5-3C9D-4722-B0E8-30C4395062F5Q38665164-E6B2D051-73A0-4CE7-BEF6-B5FE628EC170Q38669790-E612546C-5632-48C2-B0CB-DEAFDD1718E7Q38764062-DD59329C-8EC4-4C29-BD4E-B2EF333BF5FBQ38798525-A1144D5A-69DF-4EE3-BBCC-5A1A383AA5A4Q39815639-FBA80063-D6A5-481B-B6C5-B2E59E3B73C2Q47139006-6599F9CB-CF0D-4357-90EA-AC0AD9B9289DQ47270020-36D75E29-8C96-48C5-8236-9EAF2035FC26Q47568807-7E117D07-C274-452D-884C-36304B1019FFQ47661007-62343BED-AF3C-41F2-83B6-266A111C04FEQ49846411-57418ECA-FB5D-42E1-8404-45976A86C762Q58869554-67EC116A-1850-4ED0-9594-4155DFEA4C3A
P2860
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Comparative clinical pharmacok ...... first-in-human Phase 1 studies
@ast
Comparative clinical pharmacok ...... first-in-human Phase 1 studies
@en
Comparative clinical pharmacok ...... first-in-human Phase 1 studies
@nl
type
label
Comparative clinical pharmacok ...... first-in-human Phase 1 studies
@ast
Comparative clinical pharmacok ...... first-in-human Phase 1 studies
@en
Comparative clinical pharmacok ...... first-in-human Phase 1 studies
@nl
prefLabel
Comparative clinical pharmacok ...... first-in-human Phase 1 studies
@ast
Comparative clinical pharmacok ...... first-in-human Phase 1 studies
@en
Comparative clinical pharmacok ...... first-in-human Phase 1 studies
@nl
P2860
P356
P1476
Comparative clinical pharmacok ...... first-in-human Phase 1 studies
@en
P2093
Antoine Deslandes
P2860
P304
P356
10.4161/MABS.28965
P407
P577
2014-01-01T00:00:00Z